Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a ...

Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inhibitor. | ...

Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026. Exiting the first quarter, J&J named (PDF) data from the phase 2b ...

It appears Braveheart Bio isn’t going to let Big Pharma take away its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug. The Tuesday IPO ...

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its ...

Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, ...

Medtronic issued a voluntary recall of 102 lots of its Harmony delivery catheter system due to a risk that their tips may detach, which could result in serious injury or death. The recall, which was ...

Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, ...

Roche’s biggest bet in the Alzheimer’s disease space may be its phase 3-stage amyloid asset, but the Swiss pharma is keeping its options open when it comes to targeting tau. Tau is one of two proteins ...

Attovia Therapeutics has filed for an IPO to secure funding for assets including a pote | Attovia Therapeutics has filed for ...

Chai Discovery has continued its whirlwind emergence, closing its third financing round in less than a year to bring its ...

Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease ...